243 filings
Page 3 of 13
8-K
wmp8k
16 May 23
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
1:47pm
8-K
oladsm0uyy6
28 Mar 23
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial
1:40pm
8-K
2fmr8f6e6ez79n7d2ezt
14 Mar 23
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions
12:58pm
8-K
llw67ox11c
7 Mar 23
Regulation FD Disclosure
4:00pm
8-K
hzbk0t94j05d3f37
17 Feb 23
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
8:46pm
NT 10-Q
kq028 dnljmd
9 Feb 23
Notice of late quarterly filing
9:40pm
8-K
aulszi
10 Jan 23
Regulation FD Disclosure
1:00pm
8-K
jg0kir6e9lf5sm
16 Dec 22
InMed Announces Results of 2022 Annual General Meeting
5:30pm
424B3
lo8ag67f
15 Dec 22
Prospectus supplement
11:42am
EFFECT
iaf p0y3bhj1pu9
15 Dec 22
Notice of effectiveness
12:15am
8-K
bbjaku13 d8sp
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
4:01pm
8-K
cpt0d92htv4mucsueij
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
8-K
ndiz4nsbsj3cxo
12 Dec 22
Changes in Registrant's Certifying Accountant
8:14pm
UPLOAD
0x2s53yvso64k9221
12 Dec 22
Letter from SEC
12:00am
CORRESP
ourpivh6wndx8z btcig
12 Dec 22
Correspondence with SEC
12:00am
D
6qx7d8odaz4vgzjc3idk
5 Dec 22
$6.00 mm in equity / options, sold $6.00 mm, 2 investors
7:25pm
8-K
kv9efai4b5mlvfa
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm